Key result
The diagnostic pathway for cardiac masses and pseudo-tumours is complex and can lead to delayed treatment, highlighting the need for accurate identification to guide therapeutic management.
Why the study?
Correctly identifying the nature of cardiac masses is essential for ideal therapeutic management, but the pathway from suspicion to final diagnosis is often troubled and may delay treatment.
Highlights the diagnostic challenges and clinical importance of correctly identifying cardiac pseudo-tumours to ensure appropriate therapeutic management.
Answers are grounded in this paper and cite their sources.
Accurate identification of cardiac masses is critical to avoid treatment delays; leaves open validation of streamlined diagnostic pathways.
Cardiac masses encompass a wide spectrum of clinico-pathological entities, including benign and malignant—both primary and secondary—tumours.1,2 A fourth, extremely heterogenous subgroup, is represented by pseudo-tumours,3,4 which are non-neoplastic lesions—such as thrombi, calcifications, cysts, or valvular nodules—not included in the current World Health Organization classification of cardiac tumours.2 It appears, therefore, essential to correctly address the masses’ nature in order to identify the ideal therapeutic management.5,6 However, the pathway from the suspicion of a cardiac neoformation to the final diagnosis is often troubled and may lead to a delayed treatment. In fact, symptoms related to the presence of a...
No takes yet. Share an insight, caveat, or question.
Foà et al. (2021) conducted a review in Cardiac masses and pseudo-tumours. The diagnostic pathway for cardiac masses and pseudo-tumours is complex and can lead to delayed treatment, highlighting the need for accurate identification to guide therapeutic management.
Synapse has enriched 10 related papers. Consider them for comparative context: